Multicenter randomized controlled trial shows efficacy and safety of rBoNT/A in subjects with glabellar lines, suggesting a new treatment option.
The first rBoNT/A (YY001) in human study demonstrated a favorable safety and tolerability profile (dose-independent) at doses of 10, 20 and 30 U in Chinese subjects with moderate-to-severe glabellar lines. It also showed dose-dependent efficacy benefit.Trial Registration: ChinaDrugTrials.org.cn identifier: CTR20221419.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: